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Although some CETP-lowering SNPs in the CETP gene are variably associated 
with improved clinical outcomes in patients with coronary artery disease (CAD), 
three low molecular weight oral CETP inhibitors (torcetrapib, dalcetrapib, and 
evacetrapib) have not shown any clinical benefits despite remarkable increases 
in HDL-cholesterol levels ranging 31-138%. Potential causes for that failure are 
discussed in terms of off-target effects of some inhibitors, potential misleading 
interpretation of genetic epidemiological surveys in CETP gene, and inadequate 
alteration in HDL function induced by the inhibitors. Possible modalities of CETP 
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Since the first failure to develop a CETP inhibitor, subsequent clinical trials of 
CETP inhibitors have been discontinued unexpectedly; torcetrapib was 
terminated in December 2006, and dalcetrapib was also terminated in May 2012 
prematurely. Recently the phase 3 trial of evacetrapib in patients with high-risk 
atherosclerotic cardiovascular disease (ACCELERATE) was terminated in 
October 2015 due to insufficient efficacy. One remaining phase 3 trial of 
anacetrapib is still in progress. The effects on lipoproteins of anacetrapib 
appeared to be similar to those of evacetrapib (1). 
 
These trials have demonstrated the difficulty in the development of CETP 
inhibitors in relying on the changes in plasma lipids and the classical theory of 
low LDL-cholesterol (LDL-C) and high HDL-cholesterol (HDL-C) by CETP 
deficiency. In support of these results, a meta-regression analysis of 51 trials in 
secondary prevention of coronary artery disease (CAD) showed no significant 
association between changes in HDL-C and risk ratios of clinical endpoints (2). 
Thus, simple measurement of HDL-C itself is not a good biomarker for morbidity 
and mortality due to CAD and strokes in clinical trials of CETP inhibitors. 
Potential role of HDL function assay will be discussed in this chapter. 
 
2. New findings in Function and Regulation of CETP 
 
CETP could promote reverse cholesterol transport as long as the LDL receptor 
and other receptors are up regulated as shown in transgenic mice. Thus, in 
circumstances leading to lower LDL-C levels, CETP activators may be beneficial 
for atherosclerosis prevention. Liver X receptor (LXR) is known as a strong 
nuclear factor inducing CETP gene expression. Etoposide, a DNA 
topoisomerase II inhibitor as used in cancer chemotherapy, is an inducer of 
CETP via LXRα (3). In addition, farnesoid X receptor (FXR) is also an activator 
for CETP gene expression (4). 
 
 In addition to plasma lipid transfer/exchange activity, CETP may have an 
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intracellular function of inter-organelle cytosolic lipid transfer activity. A reduction 
of TG storage was shown in CETP-over-expressing SW872 adipocytes, which is 
compatible with a small, active adipocyte phenotype (5). As discussed later, the 
high-CETP adipocyte phenotype may be advantageous for weight reduction on 
a low carbohydrate diet. 
 
3. Coronary artery disease (CAD) and age-associated macular 
degeneration (AMD) disease risk in association with CETP gene (Table 1) 
 
In the large prospective cohort studies, protective effects on CAD were expected 
in the lower CETP and higher HDL alleles of TaqIB2 (intron 1, +279G>A 
rs708272) and -629C>A (rs1800775) including the Women’s Genome Health 
Study and the Copenhagen City Heart Study (6,7).  
 
 The effect of the TaqIB allele was recently evaluated with a meta-analysis 
using a Mendelian randomization approach. However, the association was 
between low CETP- high HDL and a reduction in CAD risk was marginally 
significant (8). It appears that the CAD risk reduction due to TaqIB polymorphism 
is strengthened in populations having low smoking rates or low HDL-C levels. In 
such a meta-analysis, ethnical differences and population characteristics 
(whether it is community or hospital based) are important, since a hospital-based 
population tends to be enriched for previous vascular disease and statin use.  
 
 In a genome-wide approach several potentially important SNPs were identified 
(9). Using the upstream promoter SNPs such as -2568 C>A or G>T (rs3764261) 
and -2708G>A (rs12149545) as well as TaqIB, it was not confirmed that low 
CETP allele was protective against CAD in the secondary prevention setting (10). 
Moreover, reduced protection against MI by statin was associated with in the low 
CETP allele (11). Thus, in these circumstances, selection bias of excess 
inclusion of cases with high CETP genotype in the CAD category is possible. 
Also, a positive pharmacological interaction between statin use and a high CETP 
genotype needs to be considered, since patients with TaqIB2, a low CETP 
genotype, is resistant to statin therapy as shown in the REGRESS cohort (12). 
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Similarly, low CETP levels are pro-atherogenic in several studies of secondary 
prevention and/or statin treatment. 
 
 Although the Framingham Heart Study showed that low CETP-high HDL due to 
TaqIB2 was protective against CAD, lower CETP activity was associated with 
increased CAD risk in a subsequent study (13). Thus, it is important to define 
causes of lower CETP activity, which is by genetic or environmental. Smoking, 
infection, and diabetes are potential causes lowering CETP activity. In the Asian 
Indian Diabetic Cohort, -2568C>A was associated with increased HDL levels as 
well as hypertension. Also, low CETP activity was associated with increased risk 
of CAD in this cohort. Additionally, the Suita Study reported that rs3764261 
manifests increased HDL-C levels but increased CAD risk in the Japanese (14). 
In that study, the minor allele of A was related with increased HDL-cholesterol 
levels, but it was more prevalent in cases with MI (OR=1.13, p=0.02). However, 
such an association was not replicated in another study (15). 
 
 Exon 9 is known as the alternative cassette exon, so mRNA splicing out of the 
sequence encoded by the exon 9 would result in inactive protein formation. 
Papp et al demonstrated that two SNPs (rs9930761 and rs5883) in intron 8 and 
exon 9 were determinants for efficacy of alternative splicing in the human liver, 
the former SNP is located in the branch site of intron 8, and the latter SNP 
altering the exonic splicing enhancer sequence (16)(Table 1). The rare 
combination of SNPs (rs5883T/rs9930761C) was associated with increased 
HDL-C levels, but also with increased incidence of MI, stroke, and all-cause 
mortality in males in the secondary prevention cohort of INVEST (see discussion 
of the TaqIB study). The rs5883T SNP increased the Δexon 9 transcript, 
resulting in lower CETP activity, as shown in transfection studies using the 
exons 8-10 mini-gene construct in HepG2 and HEK293 cells (17). 
 
 The D442G allele (exon 15 A>G, rs2303790) was a risk factor for AMD in East 
Asians (18), but it appeared to be protective for CAD (19). D442G showed the 
strongest association with HDL-C, while D allele showed a tendency to 
associate with CAD (OR=1.20, p=0.02) (15). It is likely that the apoE2 isoform 
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works as a risk for AMD, but it is protective factor for CAD. On the contrary, 
apoE4 is a protective factor for AMD, but it is a risk factor for CAD. Although 
retinal drusen and arterial plaques are both contain lipoproteins, the orientation 
from vascular lumen was opposite; drusen progression towards the retinal 
pigment epithelium is away from the choriocapillary vessels, but plaque 
progression was towards the vascular lumen in atherosclerosis (20). We 
observed a female in the seventies with complete CETP deficiency and no AMD 
(unpublished observation). Thus, any relationship between AMD and CETP 
deficiency needs to be established. 
 
 In the Omagari study, where the Japanese type mutation of intron14 G (+1)>A 
was enriched, a case-control study was examined in a voluntary subset of 
population with hyperalphalipoproteinemia with HDL-C > 100 mg/dL (21). In that 
study, hyperalphalipoproteinemia with lower CETP mass (1.7 mg/L vs. 
non-CETP deficiency 2.8 mg/L) was associated with cardiovascular disease and 
ischemic strokes, particularly in females. Since the CETP-deficient 
hyperalphalipoproteinemic group included 2 homozygotes and 69 heterozygotes, 
that finding would reflect clinical characteristics of heterozygous CETP 
deficiency caused by intron14 G(+1)>A mutation. This is contrast with the 




4. Role of CETP activity in adipocyte, metabolic syndrome, and diet 
therapy for weight reduction 
 
A diet-lipid interaction was found in between the -2568CC genotype and a low 
carbohydrate, high fat weight-loss diet (23). In that study, the CC genotype, 
associated with higher CETP activity, had lower baseline HDL-C levels and 
increased HDL-C response and decreased TG. 
 
 These data suggested that a high CETP genotype might improve the plasma 
lipoprotein profile during body weight reduction on a low carbohydrate diet. In 
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contrary, the low CETP genotype of I405V was associated with visceral fat 
accumulation in response to overfeeding (24). CETP may promote intracellular 
TG transport, because cytosolic lipid transfer activity has been proposed as a 
CETP function. 
 
5. HDL function and anti-inflammatory effects in CETP deficiency and 
CETP inhibitor (Figure 1) 
 
The preβ1HDL level was increased in the anacetrapib treatment of dyslipidemic 
hamsters (25), which is compatible with findings in human with homozygous 
CETP deficiency but not in heterozygotes. Evacetrapib increased cholesterol 
efflux capacity and preβ1HDL levels in dyslipidemic patients (26). However, a 
recent simulation study of HDL remodeling demonstrated that a CETP inhibitor 
of RG7232 could not increase preβ1HDL levels (27). 
 
 CETP deficiency produces large HDL2 particles, but no significant effects on 
HDL3. HDL2 could be good acceptor of cholesterol efflux capacity via SR-BI in 
Fu5AH cells (28), whereas HDL3 is an acceptor of cholesterol efflux via ABCA1 
in LXR agonist treated J774 cells. HDL-TG levels and the HDL-TG/PL ratio were 
negatively correlated with cholesterol efflux activity in Fu5AH cells (29). Thus, 
low HDL-TG seen in CETP deficiency or patients with CETP inhibitors may be 
beneficial for cholesterol efflux activity via SR-BI and ABCG1 receptors. 
 
 Anti-oxidative activity was maintained in HDL of heterozygous CETP deficiency 
(30). HDL3-S1P level had been reduced, and eNOS activation was impaired in 
CETP deficiency. However, HDL2 from CETP deficient patients were more 
effective than control HDL2 in inhibiting VCAM-1 expression (31). It is shown 
that HDL inhibited TNFα-induced MCP-1 secretion, monocyte adhesion and 
NF-κB activation in endothelial cells in the anacetrapib treated hamsters (32). 
 
 Overall, CETP inhibitors did not reduce CRP levels despite significant reduction 
of LDL and Lp(a) levels. Similarly, serum SAA levels were increased by the 
treatment of anacetrapib and atorvastatin in APOE*3Leiden.CETP mice (33). It 
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is important to know whether the inflammation is correlated with any of HDL 
function and what is the mechanism inhibiting antioxidant activity of HDL when 
CETP inhibitors are used. However, it is possible that HDL lost its antioxidant 
activity as a result when HDL protected LDL from its oxidation. 
 
 In a post hoc analysis of the MEGA study of low-dose pravastatin in the 
Japanese, mild hyperalphalipoproteinemia (HDL-C 60 - 89 mg/dL), was a 
protective factor against CAD (Hazard ratio 0.48) as compared with HDL-C <60 
mg/dL, but conclusive evidence for a reduction of CAD was not obtained in 
marked HALP in which HDL-C levels are greater than 90 mg/dL (34). Two cases 
with vasospastic angina were found in the marked hyperalphalipoproteinemic 
group (n=239). The role of this condition and unidentified other confounding 
factors must be considered in the HDL-epidemiological survey. 
 
6. Small and dense LDL, Lp(a) and proprotein convertase subtilisin/kexin 
9 (PCSK9) levels in CETP deficiency and CETP inhibitors (Figure 2) 
 
CETP inhibition increases HDL levels but also decreases LDL levels. One of the 
potential causes of lowering LDL is reduction of PCSK9 levels as shown in the 
studies of anacetrapib and a new small CETP inhibitor (K-312) (35, 36). 
Anacetrapib reduced plasma PCSK9 levels by -19% (37). It appears to be 
mediated by reduced levels of mature form of SREBP2 (38). 
 
 Since low CETP activity decreased hetero-exchange of CE and TG between 
HDL and LDL, leading to less TG in LDL, therefore small and dense LDL 
(sdLDL) was predicted to be an unlikely product after the TG lipolysis by hepatic 
lipase activity. On the contrary, high CETP activity produces more sdLDL. 
However, a recent study has suggested that while the anacetrapib decreased 
plasma levels of VLDL-IDL-LDL, but the very small and dense LDL4b fraction 
was rather increased (39). The mechanism for the discrepancy is not known, 
however, the smallest LDL4b fraction may be remained in the plasma because 
of lack of CE addition from HDL. 
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 Anacetrapib reduced Lp(a) levels by ~50% but not CRP levels (40). In vitro 
studies, Lp(a) catabolism can be regulated by PCSK9 through the LDL receptor 
(41). However, Lp(a) levels were not significantly decreased in CETP-lowering 
SNPs (7). It has been suggested that plasma Lp(a) levels are low in 
homozygous CETP deficiency. However, Lp(a) lowering effect has not been 
clearly demonstrated in heterozygous CETP deficiency yet. 
 
 The relationship between CETP, HDL, and LDL suggested that CETP might be 
a modifier gene for atherogenecity via lipoprotein levels and their functions. 
Large LDL and HDL seen in CETP deficiency are anti-atherogenic in the primary 
prevention in almost all studies, however, such an association was less clear in 
the secondary prevention or in statin users as discussed above. Mixed results in 
the secondary prevention offer more extensive studies involved functional 
assays of HDL and CETP genotyping in the near future. 
 
7. Effects on reverse cholesterol transport of CETP inhibitors 
 
Although anacetrapib promotes reverse cholesterol transport and bulk 
cholesterol excretion in hamsters, some studies suggested that CETP inhibition 
alone dose not stimulate reverse cholesterol transport (42,43). As suggested, 
additional effects mediated by the LDL-lowering drug berberine are required (44). 
Berberine induced LDL receptor production mediated by inhibition of PCSK9 
transcription, which was made thorough ubiquitin-proteasome degradation of 
hepatocyte nuclear factor 1α (45). 
 
8. Off-target effects and vascular effects of CETP inhibitors 
 
Torcetrapib increased aldosterone levels via CYP11B2 (46). However, 
endothelin-1 was also increased by torcetrapib. Endothelin-1 could be another 
cause of excess aldosterone, because endothelin-1 is a potent stimulate of 
aldosterone secretion from adrenal glands (47). However, despite no obvious 
off-target effects in dalcetrapib and evacetrapib, recent failures of clinical trials 
would suggest that an unknown problem of CETP inhibiton itself (48). Indeed, 
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dalcetrapib did not reduce the risk of recurrent cardiovascular events despite 
moderately increased HDL levels, but adverse findings of increased blood 
pressure and CRP levels were simultaneously found (49). As described, the 
failure of evacetrapib was not explained by the current HDL hypothesis, because 
the inhibitor indeed increased cholesterol efflux capacity and preβ1-HDL levels 
(26). 
 
 The failure of dalcetrapib was subsequently evaluated by genome-wide 
approach. Interestingly, the cardiovascular effect was varied by SNPs in the 
ADCY9 gene, an adenylate cyclase gene located in chromosome 16 (50). The 
AA genotype was associated with decreased of cardiovascular events, but the 
GG was on the contrary increased in the dalcetrapib treatment group. ADCY9 
may determine cAMP levels through activating β-adrenergic receptors, possibly 
involving ABCA1 efflux activity via cAMP. 
 
9. New therapy inhibiting CETP activity by other than low molecular 
weight compounds and selective TG transfer inhibition 
 
Current CETP inhibitors may have a common disadvantage in increasing CETP 
mass in HDL. In contrast, a naturally CETP deficient phenotype is expected in 
the antisense oligonucleotide. Antisense oligonucleotide inhibited CETP mRNA 
could enhance macrophage RCT, resulting in increase in fecal cholesterol 
excretion and decreased TG secretion in liver of hyperlipidemic, CETP 
transgenic, LDLR KO mice (51). 
 
 A more interesting approach might be manipulating substrate preference of 
CETP. Neutral lipid preference of CETP is varied among animal species and in 
human missense SNPs. D442G, the most common SNP in the Asian population, 
has lower preference for TG relative to CE as a substrate for lipid transfer, 
resulting in less TG gain from VLDL and more CE loss from HDL. Therefore, the 
mild CETP deficient phenotype tends to produce higher VLDL and lower HDL 
than that expected (52).  
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 Indeed, the human TP2 monoclonal antibody (mAb) and the rabbit 14-8F mAb 
against the C-terminus of CETP inhibited TG transfer greater than CE transfer 
(53). The mAb therapy would be expected to prefer CE transfer relative to TG. 
Indeed, vaccine therapy against CETP may be promising because it appears to 
be selective TG transfer inhibitor and beneficial effects of that inhibition were 
expected from the D442G SNP studies and the rabbit vaccine study (54).  
 
 Increased apoA-I was expected to result from delayed catabolism of apoA-I by 
CETP inhibitors. However, other mechanisms for increasing apoA-I via apoA-I 
production have been described. RVX-208, a selective binder to the BET 
domain protein produces its effect by an epigenetic pathway, and perhexiline 
produces its effect by modulation of Krüppel-like factor 14 (55). With these 






Torcetrapib appeared to be failed due to off-target effects on blood pressure by 
excess aldosterone despite increased HDL levels. Since dalcetrapib is a weaker 
inhibitor, therefore no effect was expected on LDL and Lp(a). It appeared that 
beneficial effects by HDL were offset by some detrimental factor in dalcetrapib. 
Again, evacetrapib is a potent inhibitor producing the expected lipoprotein 
phenotype, but the recent failure of its phase 3 clinical trial suggested using 
increased HDL and decreased LDL levels are not useful as predictors of clinical 
efficacy. The REVEAL, clinical trial of anacetrapib is still in progress, and 
lipoprotein changes are expected to be similar to those by evacetrapib. If 
anacetrapib is clinically ineffective, genome-wide pharmacogenetic approach 
would be important to determine the cause of the failure in clinical trials. 
 
 Accumulating evidence suggested that the current approach of CETP inhibition 
is pessimistic, but several directions remain to be explored for altering the target, 
including TG specific transfer inhibition or inhibitors affecting CETP production 
and translation by antisense oligonucleotide or mAb. These possibilities 
definitely need more investigation. 
 
 Confounding results have been seen in epidemiological survey of low CETP 
activity, which may be attributable to variable causes of low CETP activity, 
namely genetic or environmental. Indeed, inflammatory cytokines would 
decrease CETP expression levels as well as apoA-I. Therefore, low CETP 
activity does not always result in high HDL levels in some studies. More 
research is needed to disclose what the phenotype of low CETP but normal HDL 
levels means. 
 
 Importantly, CETP genetic epidemiological study has provided variable 
associations with clinical endpoints so far, perhaps depending in part on the 
setting of primary or secondary prevention of CAD. Additional data and careful 
analyses are still needed to clarify possible population-specific bias. Such 
research might require subclass analysis of LDL and HDL and assessment of 
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Table1.  CETP gene SNPs, location and rs numbers 
-2708G>A  Rs12149545 
-2568C>A (G>T)  Rs3764261 
-1337C>T  Rs17231506 
-629C>A  Rs1800775 
 
Intron1 TaqIB +279G>A (C>T) Rs708272 
Intron8 -40T>C Rs9930761 
Exon9  +121C>T Rs5883 
Intron9 BamHI G>A (C>T) Rs289714 
Exon14 I405V G>A Rs5882 
Intron14G>A +1G>A Mutation in Japanese 





Figure 1. HDL subclasses and their roles in lipoprotein metabolism 
 
 
Figure 2. A relationship between CETP and CAD in association studies via 
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